Review

Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations

Arie Gruzman, Gali Babai, Shlomo Sasson

Manuscript submitted April 10, 2009; resubmitted May 7, 2009; accepted May 9, 2009.

Keywords: diabetes, hyperglycemia, AMP, antihyperglycemic, drug target, energy metabolism, glucose transport, skeletal muscle, D-xylose

Abstract

In view of the epidemic nature of type 2 diabetes and the substantial rate of failure of current oral antidiabetic drugs the quest for new therapeutics is intensive. The adenosine monophosphate-activated protein kinase (AMPK) is an important regulatory protein for cellular energy balance and is considered a master switch of glucose and lipid metabolism in various organs, especially in skeletal muscle and liver. In skeletal muscles, AMPK stimulates glucose transport and fatty acid oxidation. In the liver, it augments fatty acid oxidation and decreases glucose output, cholesterol and triglyceride synthesis. These metabolic effects induced by AMPK are associated with lowering blood glucose levels in hyperglycemic individuals. Two classes of oral antihyperglycemic drugs (biguanidines and thiazolidinediones) have been shown to exert some of their therapeutic effects by directly or indirectly activating AMPK. However, side effects and an acquired resistance to these drugs emphasize the need for the development of novel and efficacious AMPK activators. We have recently discovered a new class of hydrophobic D-xylose derivatives that activates AMPK in skeletal muscles in a non insulin-dependent manner. One of these derivatives (2,4;3,5-dibenzylidene-D-xylose-diethyl-dithioacetal) stimulates the rate of hexose transport in skeletal muscle cells by increasing the abundance of glucose transporter-4 (GLUT-4) in the plasma membrane through activation of AMPK. This compound reduces blood glucose levels in diabetic mice and therefore offers a novel strategy of therapeutic intervention strategy in type 2 diabetes. The present review describes various classes of chemically-related compounds that activate AMPK by direct or indirect interactions and discusses their potential for candidate antihyperglycemic drug development.

Fulltext: HTML , PDF (453KB)

This article has been cited by other articles:

	Antihyperglycaemic activity of 2,4:3,5-dibenzylidene-D-xylose-dithioacetal in diabetic mice Gruzman A, Elgart A, Viskind O, Billauer H, Dotan S, Cohen G, Mishani E, Hoffman A, Cerasi E, Sasson S J Cell Mol Med 2011. In press
	Key regulators of mitochondrial biogenesis are increased in kidneys of growth hormone receptor knockout (GHRKO) mice Gesing A, Bartke A, Wang F, Karbownik-Lewinska M, Masternak MM Cell Biochem Funct 2011. 29(6):459-467
	Targeting the AMP-regulated kinase family to treat diabetes: a research update Sun G, Rutter GA Diabetes Manag 2011. 1(3):333-347
	Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma Siddique A, Kowdley KV Clin Liver Dis 2011. 15(2):281-296
	Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids Tang Y, Chen A Endocrinology 2010. 151(9):4168-4177
	Binding of cordycepin monophosphate to AMP-activated protein kinase and its effect on AMP-activated protein kinase activation Wang Z, Wang X, Qu K, Zhu P, Guo N, Zhang R, Abliz Z, Yu H, Zhu H Chem Biol Drug Des 2010. 76(4):340-344
	AMP-Activated protein kinase as a target for preconditioning in transplantation medicine Bouma HR, Ketelaar ME, Yard BA, Ploeg RJ, Henning RH Transplantation 2010. 90(4):353-358
	Does LKB1 Mediate Activation of Hepatic AMP-Protein Kinase (AMPK) and Sirtuin1 (SIRT1) After Roux-en-Y Gastric Bypass in Obese Rats? Peng Y, Rideout DA, Rakita SS, Gower WR Jr, You M, Murr MM J Gastrointest Surg 2010. 14(2):221-228
	Curcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cells Kim T, Davis J, Zhang AJ, He X, Mathews ST Biochem Biophys Res Commun 2009. 388(2):377-382